Highlights Celltrion, Inc.

Equities

A068270

KR7068270008

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 10/07/2025			5-day change	1st Jan Change
178,600.00 ^KRW	+1.42%		+5.74%	-0.94%

07-04	Celltrion Holdings to Buy KRW500 Billion in Celltrion Shares, Eyes Portfolio Expansion	MT
06-26	Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on May 20, 2025.	CI

Highlights

Celltrion Holdings to Buy KRW500 Billion in Celltrion Shares, Eyes Portfolio Expansion	07-04	MT
Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on May 20, 2025.	06-26	CI
Celltrion, Inc. announces an Equity Buyback for 623,053 shares.	06-26	CI
Celltrion, Inc. authorizes a Buyback Plan.	06-26	CI
Celltrion to Repurchase Shares Worth KRW100 Billion	06-26	MT
Celltrion, Inc.'s Equity Buyback announced on May 20, 2025, has expired with 629,118 shares, representing 0.27% for KRW 99,999.93 million.	06-23	CI
Celltrion Healthcare UK Limited Opens New UK Headquarters in Uxbridge, UK	06-19	CI
Celltrion, Inc. Announces U.S. FDA Approval of Additional Presentation of Steelara®? (Ustekinumab-Stba)	06-16	CI
Celltrion's YUFLYMA® (Alalimumab-Aaty) Receives FDA Interchangeability Designation for All Its Approved Doseforms and Strengthens	05-22	CI
Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on April 3, 2025.	05-20	CI
Celltrion, Inc. announces an Equity Buyback for 649,351 shares.	05-20	CI
Celltrion, Inc. authorizes a Buyback Plan.	05-20	CI
Celltrion Inc To Buy Back 100 Billion Won Worth Shares	05-19	RE
Celltrion, Inc.'s Equity Buyback announced on April 3, 2025, has closed with 631,712 shares, representing 0.29% for KRW 99,566.21 million.	05-15	CI
Celltrion, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	05-15	CI
Hyundai ADM Bio Voluntary Withdraws IND for Clinical Study of Docetaxel Combination Cancer Therapy to Focus on Immunotherapy Strategy	05-13	CI
Celltrion, Inc. to Present Six Abstracts in Inflammative Disease Week at 2025 Digestive Disease Week®?	04-28	CI
Celltrion, Inc. announces an Equity Buyback for 631,712 shares.	04-28	CI
Celltrion, Inc. authorizes a Buyback Plan.	04-27	CI
Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager	04-27	CI
U.S. FDA Grants Interchangeable Designation to Yuflyma (Alalimumab-Aaty)	04-15	CI
Celltrion Chairman, Affiliates to Buy KRW200 Billion in Stock	04-10	MT
Celltrion, Inc. announces an Equity Buyback for 589,276 shares.	04-03	CI
Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on March 21, 2025.	04-02	CI
Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on March 21, 2025.	04-02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Celltrion, Inc.

Equities

A068270

KR7068270008

Biotechnology & Medical Research

Highlights

Filters